US biotechnology company Regeneron Pharmaceuticals Inc (Regeneron) (Nasdaq:REGN) said its COVID-19 antibody cocktail, the experimental treatment that US President Donald Trump received, significantly reduced medical visits in a trial of nearly 800 patients with mild-to-moderate COVID-19, Reuters news agency reported on Thursday.

According to Regeneron, patients given the treatment, REGN-COV2, made around 57% fewer COVID-19 related medical visits than those given a placebo over a 29 day period.

This drop was around 72% in patients with one or more risk factors such as being over age 50, obesity, cardiovascular, metabolic, lung, liver or kidney disease, or an immunocompromised status.

In September 2020, the company had released early data from the trial showing the treatment reduced viral levels and improved symptoms in non-hospitalised COVID-19 patients. This new data confirm the initial findings, Regeneron said.

Also, earlier this month, the company filed with the US Food and Drug Administration seeking an EUA for the dual-antibody therapy. It said that it has shared the new data with the regulator as part of the review of its request.

According to Reuters, Regeneron had earlier said it had around 50,000 doses of its treatment ready for distribution.

Reportedly, the US government agreed in June 2020 to buy up to 300,000 doses of the antibody cocktail for USD450m.